This company has been acquired
Resumen de acción COEP
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Coeptis Therapeutics Holdings, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.35 |
| 52 Week High | US$14.00 |
| 52 Week Low | US$1.65 |
| Beta | 0 |
| 1 Month Change | 42.55% |
| 3 Month Change | 41.95% |
| 1 Year Change | -30.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.08% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| COEP | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 52.3% | 1.1% | 0.6% |
| 1Y | -30.9% | 9.4% | 23.9% |
Rentabilidad vs. Industria: COEP underperformed the US Pharmaceuticals industry which returned 8.9% over the past year.
Rentabilidad vs. Mercado: COEP underperformed the US Market which returned -21.7% over the past year.
Volatilidad de los precios
| COEP volatility | |
|---|---|
| COEP Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: COEP's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: COEP's weekly volatility has decreased from 24% to 13% over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2017 | 5 | Dave Mehalick | coeptistx.com |
Resumen de fundamentos de Coeptis Therapeutics Holdings, Inc.
| Estadísticas fundamentales de COEP | |
|---|---|
| Capitalización bursátil | US$171.54m |
| Beneficios(TTM) | -US$37.77m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-4.5x
Ratio precio-beneficio (PE)¿Está COEP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de COEP | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$37.77m |
| Beneficios | -US$37.77m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.74 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 185.0% |
¿Cómo se ha desempeñado COEP a largo plazo?
Ver rendimiento histórico y comparativa